Margriet Kwint

Chapter 5 94 Table 1 : patient and tumor characteristics from the total group and the 3 subgroup model identified by Latent Class Growth Modelling. Patient and tumor characteristics N=394 Total N (%) N=327 Subgroup 1 N (%) N=39 Subgroup 2 N (%) N=28 Subgroup 3 N (%) P-value Sex 0.014 Male 233 (59.1%) 203 (62.1%) 20 (51.3%) 10 (35.7%) Female 161 (40.9%) 124 (37.9%) 19 (48.7%) 18 (64.3%) WHO performance status 0.152 0 137 (34.8%) 106 (32.4%) 18 (46.2%) 13 (46.4%) 1 242 (61.4%) 209 (63.9%) 19 (48.7%) 14 (50%) 2 15 (3.8%) 12 (3.7%) 2 (5.1%) 1 (3.6%) Stage 0.759 1&2 26 (6.6%) 26 (8.0%) 0 (0%) 0 (0%) 3A 212 (53.8%) 166 (50.8%) 26 (66.7%) 20 (71.4%) 3B 156 (39.6%) 135 (41.3%) 13 (33.3%) 8 (28.6%) Tumor-stage 0.199 Tx-T1 70 (17.8%) 57 (17.4%) 7 (17.9%) 6 (21.4%) T2 113 (28.7%) 88 (26.9%) 16 (41%) 9 (32.1%) T3 85 (21.6%) 71 (21.7%) 6 (15.4 %) 8 (28.6%) T4 126 (32%) 111 (33.9%) 10 (25.6%) 5 (17.9%) Nodal stage 0.315 N0-1 81 (20.6%) 74 (22.6%) 5 (12.8%) 2 (7.1%) N2 232 (58.9%) 186 (56.9%) 26 (66.7%) 20 (71.4%) N3 81 (20.6%) 67 (20.5%) 8 (20.5%) 6 (21.4%) Pathology 0.119 Adenocarcinoma 127 (32.2%) 104 (31.8%) 17 (43.6%) 6 (21.4%) Squamous cell carci- noma 132 (33.5%) 114 (34.9%) 10 (25.6%) 8 (28.6%) Non-small-cell lung cancer NOS 135 (34.3%) 109 (33.3%) 12 (30.8%) 14 (50%) GTV 0.669 Median GTV 77.1 cc 76.7 cc 75.3 cc 101.1 cc Age 0.314 Mean age 62 year 62 year 63 year 60 year